IO-202

BIOLOGICAL2 trials

Sponsors

Immune-Onc Therapeutics

Conditions

AML With Monocytic DifferentiationCMMLSolid Tumor, Adult

Phase 1

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CompletedNCT04372433

Immune-Onc TherapeuticsAML With Monocytic Differentiation, CMML

Start: 2020-09-14End: 2025-01-31Updated: 2025-02-14

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

CompletedNCT05309187

Immune-Onc TherapeuticsSolid Tumor, Adult

Start: 2022-04-11End: 2024-05-31Updated: 2024-06-04

Related Papers

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.

2025-06-091 citations

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Blood2024-11-0510 citations

Integrated genetic, epigenetic, and immune landscape of <i>TP53</i> mutant AML and higher risk MDS treated with azacitidine

Therapeutic Advances in Hematology2024-01-0110 citations

P536: A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4 MAB) IN ACUTE MYELOID LEUKEMIA (AML) WITH MONOCYTIC DIFFERENTIATION AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS

HemaSphere2023-08-015 citations

747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors

Regular and Young Investigator Award Abstracts2022-11-014 citations

Abstract 1629: IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies

Cancer Research2021-07-01

A First-in-Human (FIH) Phase 1 Study of the Anti-LILRB4 Antibody IO-202 in Relapsed/Refractory (R/R) Myelomonocytic and Monocytic Acute Myeloid Leukemia (AML) and R/R Chronic Myelomonocytic Leukemia (CMML)

Blood2020-11-0411 citations